Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases

Dulai, 2014, Systematic review: monotherapy with antitumour necrosis factor alpha agents versus combination therapy with an immunosuppressive for IBD, Gut, 63, 1843, 10.1136/gutjnl-2014-307126 Dulai, 2014, Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review, Clin Gastroenterol Hepatol, 12, 1443, 10.1016/j.cgh.2014.01.021 Colombel, 2017, The safety of vedolizumab for ulcerative colitis and Crohn's disease, Gut, 66, 839, 10.1136/gutjnl-2015-311079 Dulai, 2016, The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn's disease: results from the US VICTORY Consortium, Am J Gastroenterol, 111, 1147, 10.1038/ajg.2016.236 von Elm, 2007, The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies, Lancet, 370, 1453, 10.1016/S0140-6736(07)61602-X Boland, 2015, Pseudomonas meningitis during vedolizumab therapy for Crohn's disease, Am J Gastroenterol, 110, 1631, 10.1038/ajg.2015.326 Lichtenstein, 2012, A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease, Am J Gastroenterol, 107, 1051, 10.1038/ajg.2012.89 Burmester, 2013, Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease, Ann Rheum Dis, 72, 517, 10.1136/annrheumdis-2011-201244 Loftus, 2016, Safety of long-term treatment with certolizumab pegol in patients with Crohn's disease, based on a pooled analysis of data from clinical trials, Clin Gastroenterol Hepatol, 14, 1753, 10.1016/j.cgh.2016.07.019 D’Haens, 2018, Lymphoma risk and overall safety profile of adalimumab in patients with Crohn’s disease with up to 6 years of follow-up in the PYRAMID registry, Am J Gastroenterol, 113, 872, 10.1038/s41395-018-0098-4 Lunney, 2015, Smoking prevalence and its influence on disease course and surgery in Crohn's disease and ulcerative colitis, Aliment Pharmacol Ther, 42, 61, 10.1111/apt.13239 Ananthakrishnan, 2015, Epidemiology and risk factors for IBD, Nat Rev Gastroenterol Hepatol, 12, 205, 10.1038/nrgastro.2015.34 Bhakta, 2016, Increased incidence of surgical site infection in IBD patients, Dis Colon Rectum, 59, 316, 10.1097/DCR.0000000000000550 Severs, 2016, Smoking is associated with extra-intestinal manifestations in inflammatory bowel disease, J Crohns Colitis, 10, 455, 10.1093/ecco-jcc/jjv238 Tadbiri, 2018, Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort, Aliment Pharmacol Ther, 47, 485, 10.1111/apt.14419 Axelrad, 2016, Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents, Clin Gastroenterol Hepatol, 14, 58, 10.1016/j.cgh.2015.07.037 Beaugerie, 2014, Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer, Gut, 63, 1416, 10.1136/gutjnl-2013-305763